Michael Andriole
Chief Executive Officer chez CHIMERIX, INC.
Fortune : 473 842 $ au 31/03/2024
Profil
Michael T.
Andriole is currently the President, Chief Executive Officer & Director at Chimerix, Inc. Prior to his current position, he served as the Vice President-Corporate Business Development at Eli Lilly & Co. from 2014 to 2017.
He also worked as the Chief Financial Officer at Endocyte, Inc. in 2017 and 2018.
Mr. Andriole holds an MBA from Kelley School of Business and an undergraduate degree from Williams College of Business.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
CHIMERIX, INC.
0,50% | 14/02/2024 | 447 021 ( 0,50% ) | 473 842 $ | 31/03/2024 |
Postes actifs de Michael Andriole
| Sociétés | Poste | Début |
|---|---|---|
| CHIMERIX, INC. | Chief Executive Officer | 01/08/2023 |
Anciens postes connus de Michael Andriole
| Sociétés | Poste | Fin |
|---|---|---|
| ENDOCYTE, INC. | Director of Finance/CFO | 01/12/2018 |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | 01/02/2017 |
Formation de Michael Andriole
| Kelley School of Business | Masters Business Admin |
| Williams College of Business | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| CHIMERIX, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Endocyte, Inc.
 Endocyte, Inc. Pharmaceuticals: MajorHealth Technology Endocyte, Inc. engages in the development of targeted therapies for the treatment of cancer and inflammatory diseases. It uses a proprietary technology to create novel small molecule drug conjugates and companion imaging diagnostics for personalized targeted therapies. Its small molecule drug conjugates are actively target receptors that are over-expressed on diseased cells. The company was founded by P. Ron Ellis and Philip S. Low on December 6, 1995 and is headquartered in West Lafayette, IN. | Health Technology |
